Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly

Pituitary

Volumn 13, Issue 2, 2010, Pages 115-122

  Salvatori, Roberto ^a   Nachtigall, Lisa B ^b   Cook, David M ^c   Bonert, Vivien ^d,e   Molitch, Mark E ^f   Blethen, Sandra ^g   Chang, Stephen ^g  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g IPSEN   (France)

Author keywords

Acromegaly; Lanreotide; Octreotide; Self administration; Somatostatin analogue

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; CYCLOPEPTIDE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ABDOMINAL PAIN; ACROMEGALY; ADULT; ALOPECIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; FEMALE; FLATULENCE; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HUMAN; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NAUSEA; OBESITY; OSTEOARTHRITIS; PANCREATITIS; PRIORITY JOURNAL; THYROID CANCER; AGED; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACROMEGALY; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 77955877150     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-009-0207-x     Document Type: Article

References (13)

1. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558-2573
2. Giustina A, Barkan A, Chanson P et al (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31:820-838
3. Shih HA, Loeffler JS (2008) Radiation therapy in acromegaly. Rev Endocr Metab Disord 9:59-65
4. Newman CB, Melmed S, George A et al (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040
5. Carlsen SM, Lund-Johansen M, Schreiner T et al (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984-2990
6. Melmed S, Casanueva F, Cavagnini F et al (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737-740
7. Melmed S, Sternberg R, Cook D et al (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405-4410
8. Bronstein M, Musolino N, Jallad R et al (2005) Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 63:514-519
9. Bevan JS, Newell-Price J, Wass JA et al (2008) Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 68:343-349
10. Caron P, Beckers A, Cullen DR et al (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99-104
11. Machado EO, Taboada GF, Neto LV et al (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18:389-393
12. Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94:523-527
13. Yetkin DO, Boysan SN, Tiryakioglu O, Yalin AS, Kadioglu P (2007) Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide. Endocr J 54:459-464